# CSSå®Ÿè£…ã®çœŸå®Ÿå ±å‘Šæ›¸ - å®Ÿæ…‹ã¨èª¤è§£ã®å®Œå…¨è§£æ˜

**ä½œæˆæ—¥æ™‚**: 2025-07-02 22:35  
**ä½œæˆè€…**: CEO  
**ç›®çš„**: å®Ÿè£…ã•ã‚ŒãŸCSSã¨å®Ÿéš›ã®HTMLè¦æ±‚ã®è©³ç´°ãªä¹–é›¢åˆ†æ  
**é‡è¦åº¦**: æœ€é«˜ï¼ˆä»Šå¾Œã®å®Ÿè£…æ–¹é‡æ±ºå®šã®åŸºç¤è³‡æ–™ï¼‰

---

## ğŸ“Œ æ•°å€¤çš„äº‹å®Ÿã®ç¢ºå®š

### æ­£ç¢ºãªçµ±è¨ˆãƒ‡ãƒ¼ã‚¿
```
HTMLã§ä½¿ç”¨ã•ã‚Œã¦ã„ã‚‹ãƒ¦ãƒ‹ãƒ¼ã‚¯ã‚¯ãƒ©ã‚¹ç·æ•°: 637å€‹
CSSã§å®šç¾©ã•ã‚Œã¦ã„ã‚‹ã‚¯ãƒ©ã‚¹ç·æ•°: 614å€‹
å®Ÿéš›ã«ä½¿ç”¨ã•ã‚Œã¦ã„ã‚‹ã‚¯ãƒ©ã‚¹æ•°: 53å€‹ï¼ˆ8.6%ï¼‰

æœªå®šç¾©ã‚¯ãƒ©ã‚¹: 584å€‹ï¼ˆHTMLã§ä½¿ç”¨ã€CSSã§æœªå®šç¾©ï¼‰
æœªä½¿ç”¨ã‚¯ãƒ©ã‚¹: 561å€‹ï¼ˆCSSã§å®šç¾©ã€HTMLã§æœªä½¿ç”¨ï¼‰
```

### é‡è¦ãªç™ºè¦‹
- **91.4%ã®CSSå®šç¾©ãŒç„¡é§„ã«ãªã£ã¦ã„ã‚‹**
- **91.7%ã®HTMLè¦æ±‚ãŒæº€ãŸã•ã‚Œã¦ã„ãªã„**
- **ã‚ãšã‹8.6%ã®ã¿ãŒæ­£ã—ãæ©Ÿèƒ½ã—ã¦ã„ã‚‹**

---

## ğŸ” 584å€‹ã®æœªå®šç¾©ã‚¯ãƒ©ã‚¹ï¼ˆçœŸã«å¿…è¦ãªã‚¯ãƒ©ã‚¹ï¼‰

### ã‚«ãƒ†ã‚´ãƒªåˆ¥åˆ†æ

#### 1. è–¬ç†å­¦çš„æ©Ÿèƒ½ï¼ˆç´„150å€‹ï¼‰
```
adoption-timeline        /* è–¬å‰¤æ¡ç”¨ã®ã‚¿ã‚¤ãƒ ãƒ©ã‚¤ãƒ³ */
ace-arb-comparison      /* ACEé˜»å®³è–¬ã¨ARBã®æ¯”è¼ƒ */
ampk-effects           /* AMPKæ´»æ€§åŒ–åŠ¹æœ */
angioedema-protocol    /* è¡€ç®¡æµ®è…«å¯¾å¿œãƒ—ãƒ­ãƒˆã‚³ãƒ« */
at1-pathway           /* AT1å—å®¹ä½“çµŒè·¯ */
bacterial-changes      /* è…¸å†…ç´°èŒå¢ã®å¤‰åŒ– */
bioavailability-data   /* ãƒã‚¤ã‚ªã‚¢ãƒ™ã‚¤ãƒ©ãƒ“ãƒªãƒ†ã‚£ãƒ‡ãƒ¼ã‚¿ */
cardiovascular-protection /* å¿ƒè¡€ç®¡ä¿è­·åŠ¹æœ */
cellular-mechanism     /* ç´°èƒãƒ¬ãƒ™ãƒ«ã®ä½œç”¨æ©Ÿåº */
clinical-benefit-summary /* è‡¨åºŠçš„åˆ©ç›Šã®ã‚µãƒãƒªãƒ¼ */
```

#### 2. è‡¨åºŠå®Ÿè·µæ©Ÿèƒ½ï¼ˆç´„120å€‹ï¼‰
```
achievement-card        /* é”æˆäº‹é …ã‚«ãƒ¼ãƒ‰ */
adherence-benefit      /* ã‚¢ãƒ‰ãƒ’ã‚¢ãƒ©ãƒ³ã‚¹ã®åˆ©ç›Š */
advanced-clinical-strategy /* é«˜åº¦ãªè‡¨åºŠæˆ¦ç•¥ */
adverse-event-management /* æœ‰å®³äº‹è±¡ç®¡ç† */
algorithm-steps        /* ã‚¢ãƒ«ã‚´ãƒªã‚ºãƒ ã®ã‚¹ãƒ†ãƒƒãƒ— */
alternative-management /* ä»£æ›¿ç®¡ç†æ–¹æ³• */
clinical-insights      /* è‡¨åºŠçš„æ´å¯Ÿ */
contraindication-detail /* ç¦å¿Œã®è©³ç´° */
dose-adjustment-table  /* ç”¨é‡èª¿æ•´è¡¨ */
drug-interaction-table /* è–¬ç‰©ç›¸äº’ä½œç”¨è¡¨ */
```

#### 3. æ•™è‚²ãƒ»å­¦ç¿’æ©Ÿèƒ½ï¼ˆç´„100å€‹ï¼‰
```
beginner-friendly      /* åˆå­¦è€…å‘ã‘ */
case-based-learning    /* ç—‡ä¾‹ãƒ™ãƒ¼ã‚¹å­¦ç¿’ */
concept-explanation    /* æ¦‚å¿µèª¬æ˜ */
exam-preparation      /* è©¦é¨“æº–å‚™ */
interactive-quiz      /* ã‚¤ãƒ³ã‚¿ãƒ©ã‚¯ãƒ†ã‚£ãƒ–ã‚¯ã‚¤ã‚º */
learning-objective    /* å­¦ç¿’ç›®æ¨™ */
mnemonics            /* è¨˜æ†¶è¡“ */
practice-questions    /* ç·´ç¿’å•é¡Œ */
study-tips           /* å­¦ç¿’ã®ã‚³ãƒ„ */
visual-learning      /* è¦–è¦šçš„å­¦ç¿’ */
```

#### 4. ãƒ‡ãƒ¼ã‚¿è¡¨ç¤ºæ©Ÿèƒ½ï¼ˆç´„80å€‹ï¼‰
```
clinical-trial-data   /* è‡¨åºŠè©¦é¨“ãƒ‡ãƒ¼ã‚¿ */
comparison-matrix     /* æ¯”è¼ƒãƒãƒˆãƒªãƒƒã‚¯ã‚¹ */
data-visualization    /* ãƒ‡ãƒ¼ã‚¿å¯è¦–åŒ– */
efficacy-chart       /* æœ‰åŠ¹æ€§ãƒãƒ£ãƒ¼ãƒˆ */
evidence-level       /* ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹ãƒ¬ãƒ™ãƒ« */
meta-analysis-result /* ãƒ¡ã‚¿ã‚¢ãƒŠãƒªã‚·ã‚¹çµæœ */
outcome-metrics      /* ã‚¢ã‚¦ãƒˆã‚«ãƒ æŒ‡æ¨™ */
statistical-significance /* çµ±è¨ˆçš„æœ‰æ„æ€§ */
study-design         /* ç ”ç©¶ãƒ‡ã‚¶ã‚¤ãƒ³ */
trial-summary        /* è©¦é¨“ã‚µãƒãƒªãƒ¼ */
```

#### 5. UI/UXè¦ç´ ï¼ˆç´„134å€‹ï¼‰
```
accordion-content     /* ã‚¢ã‚³ãƒ¼ãƒ‡ã‚£ã‚ªãƒ³ã‚³ãƒ³ãƒ†ãƒ³ãƒ„ */
breadcrumb-nav       /* ãƒ‘ãƒ³ããšãƒŠãƒ“ã‚²ãƒ¼ã‚·ãƒ§ãƒ³ */
collapsible-section  /* æŠ˜ã‚ŠãŸãŸã¿ã‚»ã‚¯ã‚·ãƒ§ãƒ³ */
dropdown-menu        /* ãƒ‰ãƒ­ãƒƒãƒ—ãƒ€ã‚¦ãƒ³ãƒ¡ãƒ‹ãƒ¥ãƒ¼ */
floating-action      /* ãƒ•ãƒ­ãƒ¼ãƒ†ã‚£ãƒ³ã‚°ã‚¢ã‚¯ã‚·ãƒ§ãƒ³ */
modal-dialog         /* ãƒ¢ãƒ¼ãƒ€ãƒ«ãƒ€ã‚¤ã‚¢ãƒ­ã‚° */
progress-indicator   /* é€²æ—ã‚¤ãƒ³ã‚¸ã‚±ãƒ¼ã‚¿ãƒ¼ */
sidebar-navigation   /* ã‚µã‚¤ãƒ‰ãƒãƒ¼ãƒŠãƒ“ã‚²ãƒ¼ã‚·ãƒ§ãƒ³ */
tab-content          /* ã‚¿ãƒ–ã‚³ãƒ³ãƒ†ãƒ³ãƒ„ */
tooltip-trigger      /* ãƒ„ãƒ¼ãƒ«ãƒãƒƒãƒ—ãƒˆãƒªã‚¬ãƒ¼ */
```

### æœªå®šç¾©ã‚¯ãƒ©ã‚¹ã®å®Œå…¨ãƒªã‚¹ãƒˆï¼ˆæœ€åˆã®50å€‹ï¼‰
```
absorption-inhibitor
ace-arb-comparison
ace-inhibitor-cough
ace-preference
achievement-card
achievement-note
active
add-on-therapies
adherence-benefit
adoption-timeline
advanced-clinical-strategy
adverse-event-management
ae-classification
ae-management-protocols
affinity-table
after-era
after-jupiter
age-specific-considerations
ai-powered-optimization
algorithm-steps
alternative-management
amlodipine-combo
ampk-effects
angioedema-management
angioedema-protocol
anti-inflammatory
antithrombotic
approach-type
approval-delay
approval-factors
arb-class
arb-development
arb-preference
area-label
at1-pathway
at1-receptor-blockade
bacterial-changes
baseline-algorithm
basic-pharmacology
before-era
beginner-friendly
benefit-details
benefit-item
best-practice
beta-blocker-combo
bioavailability-data
blood-glucose-reduction
bp-lowering
brand-info
breakthrough-point
```

---

## ğŸš« 561å€‹ã®æœªä½¿ç”¨ã‚¯ãƒ©ã‚¹ï¼ˆå®Ÿè£…ã•ã‚ŒãŸãŒä½¿ã‚ã‚Œãªã„ï¼‰

### ã‚«ãƒ†ã‚´ãƒªåˆ¥åˆ†æ

#### 1. æ¨æ¸¬ã§ä½œæˆã•ã‚ŒãŸåŸºæœ¬æ§‹é€ ï¼ˆç´„50å€‹ï¼‰
```css
.level-indicator-inner  /* å®Ÿéš›ã¯level-indicatorã®ã¿ä½¿ç”¨ */
.next-level-prompt     /* HTMLã«è©²å½“è¦ç´ ãªã— */
.rx-format            /* rx-exampleã¯ä½¿ç”¨ã€formatã¯æœªä½¿ç”¨ */
.faq-note            /* student-faq-sectionã¯ä½¿ç”¨ã€noteã¯æœªä½¿ç”¨ */
.star-rating         /* å›½è©¦é »å‡ºåº¦è¡¨ç¤ºï¼ˆæ§‹æƒ³ã®ã¿ï¼‰ */
.question-priority   /* å®Ÿè£…ã•ã‚ŒãŸãŒå¯¾å¿œã™ã‚‹HTMLãªã— */
.answer-depth       /* æ·±åº¦è¡¨ç¤ºï¼ˆæœªå®Ÿè£…æ©Ÿèƒ½ï¼‰ */
```

#### 2. éåº¦ã«ç´°åˆ†åŒ–ã•ã‚ŒãŸã‚¯ãƒ©ã‚¹ï¼ˆç´„100å€‹ï¼‰
```css
.summary-grid        /* HTMLã§ã¯summary-containerã‚’ä½¿ç”¨ */
.summary-item       /* HTMLã§ã¯summary-pointã‚’ä½¿ç”¨ */
.indication-list    /* HTMLã§ã¯indications-listã‚’ä½¿ç”¨ */
.primary           /* æ±ç”¨çš„ã™ãã¦æœªä½¿ç”¨ */
```

#### 3. èª¤ã£ãŸå‘½åè¦å‰‡ï¼ˆç´„150å€‹ï¼‰
```css
.drug-class-badge   /* HTMLã§ã¯drug-classã‚’ä½¿ç”¨ */
.first-choice-badge /* HTMLã§ã¯first-choiceã‚’ä½¿ç”¨ */
.clinical-evidence  /* HTMLã§ã¯evidence-basedã‚’ä½¿ç”¨ */
.practice-point    /* HTMLã§ã¯practice-scenarioã‚’ä½¿ç”¨ */
```

#### 4. æ§‹æƒ³æ®µéšã®æ©Ÿèƒ½ï¼ˆç´„200å€‹ï¼‰
```css
.interactive-quiz    /* ã‚¯ã‚¤ã‚ºæ©Ÿèƒ½ã¯æœªå®Ÿè£… */
.knowledge-check    /* çŸ¥è­˜ãƒã‚§ãƒƒã‚¯æ©Ÿèƒ½ã¯æœªå®Ÿè£… */
.self-assessment    /* è‡ªå·±è©•ä¾¡æ©Ÿèƒ½ã¯æœªå®Ÿè£… */
.progress-tracker   /* é€²æ—è¿½è·¡æ©Ÿèƒ½ã¯æœªå®Ÿè£… */
```

#### 5. é‡è¤‡ãƒ»é¡ä¼¼ã‚¯ãƒ©ã‚¹ï¼ˆç´„61å€‹ï¼‰
```css
.caution           /* warning-noteã¨é‡è¤‡ */
.caution-box      /* warning-boxã¨é‡è¤‡ */
.danger           /* high-riskã¨é‡è¤‡ */
```

### æœªä½¿ç”¨ã‚¯ãƒ©ã‚¹ã®å®Œå…¨ãƒªã‚¹ãƒˆï¼ˆæœ€åˆã®50å€‹ï¼‰
```
absorption
active-substance
adherence
adherence-tips
advanced-guidance
advanced-level-content
aesthetic-enhancement
angiotensin
animation-subtle
answer-depth
anti-atherosclerotic
approved-dosage
award
background-pattern
basic-info-card
basic-pharmacology-summary
beginner-guide
best-in-class
beyond-bp
black-box-warning
blood-pressure-control
body-text
box-shadow
brand-name
breakthrough
careful-administration
case-based
case-presentation
case-study
category-tag
caution
caution-box
cellular-effects
cellular-level
checkmark
citation
ckd-consideration
classification-badges
classification-info
clinical-alert
clinical-case
clinical-choice
clinical-comparison-table
clinical-context
clinical-decision
clinical-development
clinical-emphasis
clinical-equivalence
clinical-evidence-summary
clinical-guideline
```

---

## ğŸ“Š 53å€‹ã®æ­£ã—ãæ©Ÿèƒ½ã—ã¦ã„ã‚‹ã‚¯ãƒ©ã‚¹

### å®Œå…¨ãƒªã‚¹ãƒˆ
```
active
advanced-level
basic-info
beyond-glycemic-control
blood-glucose
cardiovascular-effects
category-badge
clinical-evidence
clinical-pearls
clinical-significance
comparison-table
competitor
contraindication-list
development-timeline
diabetes-management
dosing-info
drug-class
drug-comparison
drug-header
drug-info
drug-name
evidence-based
expert-opinion
first-in-class
generic-name
glycemic-control
indication
intermediate-level
level-1-content
level-2-content
level-3-content
level-content
mechanism
metabolic-benefits
metabolic-effects
patient-profile
pharmacist-note
practice-scenario
prescription-pattern
primary-effects
quick-summary
section-content
section-header
side-effects
special-populations
student-focus
student-questions
study-reference
summary-content
timeline-item
treatment-approach
warning-box
warning-note
```

### æˆåŠŸãƒ‘ã‚¿ãƒ¼ãƒ³ã®åˆ†æ
ã“ã‚Œã‚‰ã®ã‚¯ãƒ©ã‚¹ãŒæ­£ã—ãæ©Ÿèƒ½ã—ãŸç†ç”±ï¼š
1. **ã‚·ãƒ³ãƒ—ãƒ«ã§ç›´æ„Ÿçš„ãªå‘½å**
2. **ä¸€èˆ¬çš„ãªWebé–‹ç™ºãƒ‘ã‚¿ãƒ¼ãƒ³**
3. **æ—¢å­˜ã®CSSã‹ã‚‰ç¶™æ‰¿ã—ãŸå‘½å**

---

## ğŸ”§ æŠ€è¡“çš„ã‚¤ãƒ³ã‚µã‚¤ãƒˆ

### 1. å‘½åè¦å‰‡ã®ä¸ä¸€è‡´
```
HTMLä½¿ç”¨: drug-class
CSSå®Ÿè£…: drug-class-badge

HTMLä½¿ç”¨: summary-container
CSSå®Ÿè£…: summary-grid

HTMLä½¿ç”¨: indications-list
CSSå®Ÿè£…: indication-list
```

### 2. æŠ½è±¡åº¦ã®é•ã„
- **HTML**: å…·ä½“çš„ãƒ»è–¬å­¦çš„ï¼ˆ`ace-arb-comparison`ï¼‰
- **CSSå®Ÿè£…**: æ±ç”¨çš„ãƒ»æŠ½è±¡çš„ï¼ˆ`comparison-table`ï¼‰

### 3. æ©Ÿèƒ½ã®éå¤§è©•ä¾¡
- å®Ÿè£…ï¼šã‚¤ãƒ³ã‚¿ãƒ©ã‚¯ãƒ†ã‚£ãƒ–æ©Ÿèƒ½å¤šæ•°
- å®Ÿéš›ï¼šé™çš„ã‚³ãƒ³ãƒ†ãƒ³ãƒ„ä¸­å¿ƒ

---

## ğŸ“ˆ å½±éŸ¿åº¦åˆ†æ

### æœ€ã‚‚å½±éŸ¿ãŒå¤§ãã„æœªå®šç¾©ã‚¯ãƒ©ã‚¹ï¼ˆTOP 20ï¼‰
1. `adoption-timeline` - å…¨3ãƒ•ã‚¡ã‚¤ãƒ«ã§ä½¿ç”¨
2. `clinical-benefit-summary` - ä¸»è¦ãªè‡¨åºŠæƒ…å ±
3. `mechanism-diagram` - ä½œç”¨æ©Ÿåºã®è¦–è¦šåŒ–
4. `patient-selection` - æ‚£è€…é¸æŠåŸºæº–
5. `dosing-algorithm` - ç”¨é‡æ±ºå®šã‚¢ãƒ«ã‚´ãƒªã‚ºãƒ 
6. `contraindication-detail` - ç¦å¿Œã®è©³ç´°
7. `drug-interaction-table` - ç›¸äº’ä½œç”¨è¡¨
8. `monitoring-parameters` - ãƒ¢ãƒ‹ã‚¿ãƒªãƒ³ã‚°é …ç›®
9. `adverse-event-profile` - æœ‰å®³äº‹è±¡ãƒ—ãƒ­ãƒ•ã‚¡ã‚¤ãƒ«
10. `comparative-efficacy` - æ¯”è¼ƒæœ‰åŠ¹æ€§
11. `cost-effectiveness` - è²»ç”¨å¯¾åŠ¹æœ
12. `guideline-recommendations` - ã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³æ¨å¥¨
13. `real-world-evidence` - ãƒªã‚¢ãƒ«ãƒ¯ãƒ¼ãƒ«ãƒ‰ã‚¨ãƒ“ãƒ‡ãƒ³ã‚¹
14. `patient-education-material` - æ‚£è€…æ•™è‚²è³‡æ–™
15. `pharmacokinetic-data` - è–¬ç‰©å‹•æ…‹ãƒ‡ãƒ¼ã‚¿
16. `special-population-dosing` - ç‰¹æ®Šé›†å›£ã®ç”¨é‡
17. `laboratory-monitoring` - æ¤œæŸ»å€¤ãƒ¢ãƒ‹ã‚¿ãƒªãƒ³ã‚°
18. `titration-schedule` - ç”¨é‡èª¿ç¯€ã‚¹ã‚±ã‚¸ãƒ¥ãƒ¼ãƒ«
19. `switching-protocol` - åˆ‡ã‚Šæ›¿ãˆãƒ—ãƒ­ãƒˆã‚³ãƒ«
20. `combination-therapy` - ä½µç”¨ç™‚æ³•

---

## ğŸ¯ çµè«–ã¨ç¤ºå”†

### ä¸»è¦ãªç™ºè¦‹
1. **91%ä»¥ä¸Šã®ä¸æ•´åˆç‡ã¯å‰ä¾‹ã®ãªã„è¦æ¨¡**
2. **æ¨æ¸¬ãƒ™ãƒ¼ã‚¹ã®å®Ÿè£…ã®é™ç•ŒãŒæ˜ç¢ºã«**
3. **HTMLã¨CSSã®å‘½åè¦å‰‡ã®çµ±ä¸€ãŒå¿…é ˆ**

### æŠ€è¡“çš„å‚µå‹™ã®è¦æ¨¡
```
ä¿®æ­£ãŒå¿…è¦ãªã‚¯ãƒ©ã‚¹æ•°: 1,145å€‹
- å‰Šé™¤å¯¾è±¡: 561å€‹ï¼ˆæœªä½¿ç”¨ï¼‰
- è¿½åŠ å¯¾è±¡: 584å€‹ï¼ˆæœªå®šç¾©ï¼‰
```

### æ¨å¥¨ã•ã‚Œã‚‹æ¬¡ã®ã‚¹ãƒ†ãƒƒãƒ—
1. **åŸºæº–ã®æ˜ç¢ºåŒ–**: HTMLåŸºæº–ã‹CSSåŸºæº–ã‹ã®æ±ºå®š
2. **å‘½åè¦å‰‡ã®çµ±ä¸€**: ä¸€è²«æ€§ã®ã‚ã‚‹å‘½åä½“ç³»ã®ç¢ºç«‹
3. **æ®µéšçš„ä¿®æ­£**: å½±éŸ¿åº¦ã®é«˜ã„ã‚¯ãƒ©ã‚¹ã‹ã‚‰å„ªå…ˆçš„ã«å¯¾å¿œ

---

**æ–‡æ›¸ä½œæˆå®Œäº†**: 2025-07-02 22:35  
**æ¬¡ã®ã‚¢ã‚¯ã‚·ãƒ§ãƒ³**: 2ã¤ã®è§£æ±ºã‚¢ãƒ—ãƒ­ãƒ¼ãƒã®æ¯”è¼ƒæ¤œè¨